Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2026-02-03 @ 7:24 AM
Study NCT ID:
NCT00565708
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-02
First Post:
2007-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Philippines', 'Taiwan', 'Thailand']}, 'conditionBrowseModule': {'meshes': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D003110', 'term': 'Colonic Neoplasms'}, {'id': 'D012004', 'term': 'Rectal Neoplasms'}], 'ancestors': [{'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001241', 'term': 'Aspirin'}], 'ancestors': [{'id': 'D012459', 'term': 'Salicylates'}, {'id': 'D062385', 'term': 'Hydroxybenzoates'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-05-09', 'size': 711802, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-01-29T09:45', 'hasProtocol': True}, {'date': '2023-02-20', 'size': 8592245, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-01-29T09:51', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1587}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2008-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-01', 'completionDateStruct': {'date': '2024-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-01-31', 'studyFirstSubmitDate': '2007-11-29', 'studyFirstSubmitQcDate': '2007-11-29', 'lastUpdatePostDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2007-11-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2024-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Disease-free survival', 'timeFrame': '5 years', 'description': 'Recurrence data documented'}], 'secondaryOutcomes': [{'measure': 'Overall survival', 'timeFrame': '5 years', 'description': 'Death data documented'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['stage II colon cancer', 'stage III colon cancer', 'stage II rectal cancer', 'stage III rectal cancer'], 'conditions': ['Colorectal Cancer']}, 'referencesModule': {'references': [{'pmid': '32293940', 'type': 'BACKGROUND', 'citation': 'Segelov E, Prenen H, Day D, Macintyre CR, Foo EMJ, Ali R, Wang Q, Wei X, Lopes GL Jr, Ding K, Chen G, Chia JWK, Toh HC; ASCOLT Investigators. Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. JCO Glob Oncol. 2020 Apr;6:585-588. doi: 10.1200/GO.20.00072. No abstract available.'}, {'pmid': '37364220', 'type': 'BACKGROUND', 'citation': 'Day D, Toh HC, Ali R, Foo EMJ, Simes J, Chia JWK, Segelov E; ASCOLT Investigators. Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial. JCO Glob Oncol. 2023 Jun;9:e2300040. doi: 10.1200/GO.23.00040.'}, {'pmid': '39824200', 'type': 'DERIVED', 'citation': 'Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC. Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 Mar;10(3):198-209. doi: 10.1016/S2468-1253(24)00387-X. Epub 2025 Jan 14.'}, {'pmid': '22168568', 'type': 'DERIVED', 'citation': 'Ali R, Toh HC, Chia WK; ASCOLT Trial Investigators. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011 Dec 14;12:261. doi: 10.1186/1745-6215-12-261.'}]}, 'descriptionModule': {'briefSummary': 'We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally.\n\nSTUDY OBJECTIVE\n\nTo assess the effectiveness of Aspirin against placebo control in patients with dukes C or high risk dukes B colorectal cancer in terms of Disease Free Survival (DFS) and Overall Survival (OS)\n\nPrimary endpoints\n\n* DFS among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups);\n* DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer).\n\nSecondary endpoints\n\n* Overall survival (OS) over 5 years\n* DFS and OS in\n\n * Chinese, Malay, Indian and other ethnic groups\n * Resected high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer sub-groups, individually\n * Compliant versus non-compliant subjects\n * PIK3CA mutated tumors (where samples are available)', 'detailedDescription': "Aspirin in patients with dukes C or high risk dukes B colorectal cancer can improve survival in this patient population over placebo control.\n\nEligible patients will be randomized to treatment arms, using the following stratification factors:\n\n* Study Centre\n* Tumour Type\n* Type of adjuvant chemotherapy received(exposed/not exposed to oxaliplatin\n\nPatients will be randomized over a 5 years' time period. After randomization, patient will have 3 monthly assessments with treatment for 3 years followed by 6 monthly assessments for additional 2 years follow-up"}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria\n\n* Male or female outpatient of ≥ 18 years of age or ≥ country's legal age for adult consent\n* Dukes C colon cancer, high risk Dukes B colon cancer, Dukes B rectal cancer or Dukes C rectal cancer (see Appendix 1 for definition of High Risk Dukes B)\n* Undergone complete resection of primary tumour\n* Completed standard therapy ( at least 3 months of chemotherapy ± radiotherapy )\n* Within 120 days of completion of standard therapy (surgery, chemotherapy ± radiotherapy)\n* ECOG performance status 0 to 2\n* Satisfactory haematological or biochemical functions (tests should be carried out within 8 weeks prior to randomisation): Results of clinical investigations carried out within 8 weeks prior to randomisation can be used in place of the required screening investigations. Patients with mild laboratory abnormalities can be included at the discretion by the site principal investigator, and after approval by ASCOLT Trial Management Group\n* ANC ≥ 1.0 x 109/L\n* Platelets ≥ 100 x 109/L\n* Creatinine clearance ≥ 30 mL/min\n* Total bilirubin ≤ 2.0 x the upper limit normal\n* AST \\& ALT ≤ 5 x the upper limit normal\n* Completed the following investigations\n* Colonoscopy(or CT colonogram(within 16 months prior to randomization)\n* Imaging of abdomen (CT or CT colonogram or MRI or PET or Ultrasound) within 16 months prior to randomization\n* Written informed consent\n\nExclusion Criteria\n\n* Pre-existing Familial adenomatous polyposis, inflammatory bowel disease or ulcerative colitis\n* Active gastritis or active peptic ulcer\n* History of continuous daily use of PPI more than 1 year prior to consent\n* Gastrointestinal bleeding within the past one year\n* Haemorrhagic diathesis (i.e. haemophilia)\n* Uncontrolled hypertension (untreated systolic blood pressure \\> 160 mmHg, or diastolic blood pressure \\> 95 mmHg)\n* History of recent cancers (except for colorectal cancers, non-melanoma skin cancers, basal cell carcinomas, squamous cell carcinomas) in the past 5 years\n* History of stroke, coronary arterial disease, angina, or vascular disease\n* Patients who are on current long term treatment (≥ 4 consecutive weeks) with Aspirin, NSAID or Cox-2 inhibitors\n* History of erosive GERD or active erosive GERD on gastroscopy.\n* Patient on active current treatment of antiplatelet agents (i.e. off-study Aspirin, clopidogrel, ticlopidine)\n* Patient receiving active treatment of anticoagulants (i.e. warfarin, low molecular weight heparins)\n* Pregnant, lactating, or not using adequate contraception\n* Patient having known allergy to NSAID or Aspirin\n* Unexplained rise of CEA (i.e. smoker with elevated CEA will not be excluded)\n* Patient on other investigational drug\n* Patients with HNPCC (Lynch Syndrome)"}, 'identificationModule': {'nctId': 'NCT00565708', 'acronym': 'ASCOLT', 'briefTitle': 'Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers', 'organization': {'class': 'OTHER', 'fullName': 'National Cancer Centre, Singapore'}, 'officialTitle': 'Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial', 'orgStudyIdInfo': {'id': 'CDR0000577892'}, 'secondaryIdInfos': [{'id': 'SINGAPORE-ICR-02', 'type': 'OTHER', 'domain': 'SCRI'}, {'id': 'SINGAPORE-ASCOLT', 'type': 'OTHER', 'domain': 'SCRI'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'acetylsalicylic acid', 'description': '200mg OD for 3 years', 'interventionNames': ['Drug: Acetylsalicylic acid']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': '200mg OD for 3 years', 'interventionNames': ['Other: placebo']}], 'interventions': [{'name': 'placebo', 'type': 'OTHER', 'description': 'Placebo Comparator', 'armGroupLabels': ['Placebo']}, {'name': 'Acetylsalicylic acid', 'type': 'DRUG', 'otherNames': ['Aspirin'], 'description': 'Adjuvant Therapy', 'armGroupLabels': ['acetylsalicylic acid']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Bankstown', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Bankstown-Lidcombe Hospital Bankstown Cancer Centre', 'geoPoint': {'lat': -33.91667, 'lon': 151.03333}}, {'city': 'Campbelltown', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Macarthur Cancer Therapy Centre', 'geoPoint': {'lat': -34.06667, 'lon': 150.81667}}, {'zip': '2050', 'city': 'Camperdown', 'state': 'New South Wales', 'country': 'Australia', 'facility': "Chris O'Brien Lifehouse, Clinical Research Centre", 'geoPoint': {'lat': -33.88965, 'lon': 151.17642}}, {'zip': '2450', 'city': 'Coffs Harbour', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Coffs Harbour Health Campus North Coast Cancer Institute', 'geoPoint': {'lat': -30.29626, 'lon': 153.11351}}, {'zip': '2050', 'city': 'Gosford', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Central Coast Cancer Centre Gosford Hospital', 'geoPoint': {'lat': -33.4244, 'lon': 151.34399}}, {'zip': '2305', 'city': 'New Lambton Heights', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Newcastle private Hospital', 'geoPoint': {'lat': -32.92466, 'lon': 151.69364}}, {'city': 'Orange', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Orange Health Service', 'geoPoint': {'lat': -33.28397, 'lon': 149.10018}}, {'zip': '2444', 'city': 'Port Macquarie', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Port Macquarie Base Hospital North Coast Cancer Institute', 'geoPoint': {'lat': -31.43084, 'lon': 152.90894}}, {'zip': '2065', 'city': 'St Leonards', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Northern Cancer Institute, St Leonards', 'geoPoint': {'lat': -33.82344, 'lon': 151.19836}}, {'city': 'Sydney', 'state': 'New South Wales', 'country': 'Australia', 'facility': "St Vincent's Hospital", 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': '2340', 'city': 'Tamworth', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Northwest Cancer Centre Tamworth Hospital', 'geoPoint': {'lat': -31.09048, 'lon': 150.92905}}, {'city': 'Tweed Heads', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'The Tweed Hospital', 'geoPoint': {'lat': -28.17671, 'lon': 153.5452}}, {'city': 'Waratah', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Calvary Mater Newcastle Hospital', 'geoPoint': {'lat': -32.90667, 'lon': 151.72647}}, {'city': 'Tiwi', 'state': 'Northern Territory', 'country': 'Australia', 'facility': 'Royal Darwin Hospital', 'geoPoint': {'lat': -12.35876, 'lon': 130.878}}, {'zip': '4814', 'city': 'Douglas', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Townsville Hospital', 'geoPoint': {'lat': -19.32394, 'lon': 146.75234}}, {'city': 'Herston', 'state': 'Queensland', 'country': 'Australia', 'facility': "Royal Brisbane and Women's Hospital", 'geoPoint': {'lat': -27.44453, 'lon': 153.01852}}, {'city': 'Toowoomba', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Toowoomba Hospital', 'geoPoint': {'lat': -27.56056, 'lon': 151.95386}}, {'zip': '5112', 'city': 'Elizabeth Vale', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Lyell McEwin Hospital', 'geoPoint': {'lat': -34.74857, 'lon': 138.66819}}, {'zip': '7000', 'city': 'Hobart', 'state': 'Tasmania', 'country': 'Australia', 'facility': 'Royal Hobart Hospital', 'geoPoint': {'lat': -42.87936, 'lon': 147.32941}}, {'city': 'Albury', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Border Medical Oncology Research Unit'}, {'zip': '3350', 'city': 'Ballarat', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Ballarat Regional Integrated Cancer Centre', 'geoPoint': {'lat': -37.56622, 'lon': 143.84957}}, {'city': 'Geelong', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Barwon Health Andrew Love Cancer Centre', 'geoPoint': {'lat': -38.14711, 'lon': 144.36069}}, {'city': 'Heidelberg', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Austin Health Cancer Clinical Trials', 'geoPoint': {'lat': -37.75, 'lon': 145.06667}}, {'city': 'Launceston', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Launceston General Hospital'}, {'zip': '3165', 'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Monash Health Medical Oncology', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '3630', 'city': 'Shepparton', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Goulburn Valley Health', 'geoPoint': {'lat': -36.38047, 'lon': 145.39867}}, {'zip': '3280', 'city': 'Warrnambool', 'state': 'Victoria', 'country': 'Australia', 'facility': 'St John of God Healthcare Southwest Oncology', 'geoPoint': {'lat': -38.38176, 'lon': 142.48799}}, {'city': 'Nedlands', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Sir Charles Gairdner Hospital', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'city': 'Subiaco', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'St John of God Hospital Subiaco', 'geoPoint': {'lat': -31.9485, 'lon': 115.8268}}, {'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Beijing University Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'city': 'Foshan', 'state': 'Guangdong', 'country': 'China', 'facility': "The First People's Hospital of Foshan City", 'geoPoint': {'lat': 23.02677, 'lon': 113.13148}}, {'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Guangdong General Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Sixth Affiliated Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Sun Yat Sen University Cancer Center', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'city': 'Zhongshan', 'state': 'Guangdong', 'country': 'China', 'facility': "Zhongshan City People's Hospital", 'geoPoint': {'lat': 22.52306, 'lon': 113.37912}}, {'city': 'Nantong', 'state': 'Jiangsu', 'country': 'China', 'facility': 'Affiliated Hospital of Nantong University', 'geoPoint': {'lat': 32.03028, 'lon': 120.87472}}, {'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'facility': 'Jinan Central Hospital', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'city': 'Yantai', 'state': 'Shandong', 'country': 'China', 'facility': 'Yantai Yuhuangding Hospital', 'geoPoint': {'lat': 37.47649, 'lon': 121.44081}}, {'zip': '23561', 'city': 'Taibei', 'state': 'Taiwan', 'country': 'China', 'facility': 'Shuang Ho Hospital', 'geoPoint': {'lat': 34.7, 'lon': 119.23333}}, {'city': 'Taibei', 'state': 'Taiwan', 'country': 'China', 'facility': 'Koo Foundation Sun Yat Sen Cancer Centre', 'geoPoint': {'lat': 34.7, 'lon': 119.23333}}, {'city': 'Taibei', 'state': 'Taiwan', 'country': 'China', 'facility': 'Taipei Medical University Hospital', 'geoPoint': {'lat': 34.7, 'lon': 119.23333}}, {'city': 'Taibei', 'state': 'Taiwan', 'country': 'China', 'facility': 'Wan Fang Hospital', 'geoPoint': {'lat': 34.7, 'lon': 119.23333}}, {'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'facility': 'The Second Affiliated Hospital of Zhejiang University', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'city': 'Hong Kong', 'country': 'China', 'facility': 'Queen Mary Hospital - Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'zip': '560029', 'city': 'Bangalore', 'country': 'India', 'facility': 'Kidwai Memorial Institute of Oncology', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'zip': '641 037', 'city': 'Coimbatore', 'country': 'India', 'facility': 'G. Kuppuswamy Naidu Memorial Hospital', 'geoPoint': {'lat': 11.00555, 'lon': 76.96612}}, {'zip': '500 082', 'city': 'Hyderabad', 'country': 'India', 'facility': "Nizam's Institute of Medical Sciences", 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'zip': '400012', 'city': 'Mumbai', 'country': 'India', 'facility': 'Tata Memorial Hospital', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'zip': '110029', 'city': 'New Delhi', 'country': 'India', 'facility': 'All India Institute of Medical Sciences', 'geoPoint': {'lat': 28.62137, 'lon': 77.2148}}, {'zip': '695011', 'city': 'Trivandrum', 'country': 'India', 'facility': 'Regional Cancer Center', 'geoPoint': {'lat': 8.4855, 'lon': 76.94924}}, {'zip': '632002', 'city': 'Vellore', 'country': 'India', 'facility': 'Christian Medical College and Hospital', 'geoPoint': {'lat': 12.9184, 'lon': 79.13255}}, {'zip': '11420', 'city': 'Jakarta', 'country': 'Indonesia', 'facility': 'Dharmais Cancer Hospital', 'geoPoint': {'lat': -6.21462, 'lon': 106.84513}}, {'city': 'Jakarta', 'country': 'Indonesia', 'facility': 'Cipto Mangunkusumo General Hospital', 'geoPoint': {'lat': -6.21462, 'lon': 106.84513}}, {'zip': '55284', 'city': 'Yogyakarta', 'country': 'Indonesia', 'facility': 'Rumah Sakit RSUP Dr. Sardjito', 'geoPoint': {'lat': -7.80139, 'lon': 110.36472}}, {'city': 'Kuching', 'state': 'Sarawak', 'country': 'Malaysia', 'facility': 'Sarawak General Hospital', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}, {'zip': '50586', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'Hospital Kuala Lumpur', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'zip': '59100', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'University of Malaysia Medical Center', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'University Kebangsaan Malaysia Medical Center', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'zip': '8140', 'city': 'Christchurch', 'country': 'New Zealand', 'facility': 'Christchurch Public Hospital', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'city': 'Dunedin', 'country': 'New Zealand', 'facility': 'Dunedin Hospital', 'geoPoint': {'lat': -45.87416, 'lon': 170.50361}}, {'zip': '11525', 'city': 'Riyadh', 'country': 'Saudi Arabia', 'facility': 'King Fahad Medical City', 'geoPoint': {'lat': 24.68773, 'lon': 46.72185}}, {'zip': '169610', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'National Cancer Centre - Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Johns Hopkins Singapore International Medical Center', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Tan Tock Seng Hospital', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Anyang-si', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'Hallym University Sacred Heart Hospital', 'geoPoint': {'lat': 37.3925, 'lon': 126.92694}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Maharagama', 'country': 'Sri Lanka', 'facility': 'National Cancer Institute', 'geoPoint': {'lat': 6.848, 'lon': 79.9265}}], 'overallOfficials': [{'name': 'John Chia, MBBS, MRCP', 'role': 'STUDY_CHAIR', 'affiliation': 'National Cancer Centre, Singapore'}, {'name': 'Raghib Ali, MBBS,MRCP', 'role': 'STUDY_CHAIR', 'affiliation': 'NYU'}, {'name': 'Han Chong Toh, MD,MBBS,MRCP', 'role': 'STUDY_CHAIR', 'affiliation': 'National Cancer Centre, Singapore'}, {'name': 'Eva Segelov, MBBS,PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Monash University, University of Bern'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Cancer Centre, Singapore', 'class': 'OTHER'}, 'collaborators': [{'name': 'Australasian Gastro-Intestinal Trials Group', 'class': 'NETWORK'}, {'name': 'INDOX Cancer Research Network', 'class': 'OTHER'}, {'name': 'University of Sydney', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Prof', 'investigatorFullName': 'Toh Han Chong', 'investigatorAffiliation': 'National Cancer Centre, Singapore'}}}}